Collaborations across Immunotherapy - Genetic TOE

USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This edition of the Genetic TOE focuses on immunotherapies. Collaborations between Bristol-Myers Squibb (BMS) and Five Prime Therapeutics for developing Immunotherapies, Celgene and Jounce Therapeutics for developing a monoclonal antibody for cancer, Merck KGaA and Pfizer for developing ligand 1 checkpoint inhibitors, and Merck & Co. and Ablynx for a Nanobody program have been profiled.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered inclu

Table of Contents

Collaborations across Immunotherapy - Genetic TOEProminent Immuno-oncology Collaborations Colony Stimulating Factor 1 Receptor Technology Used to Develop ImmunotherapiesMonoclonal Antibody Being Developed Jointly for a Range of Cancers Two Big Pharma Companies Collaborate to Develop Ligand 1 Checkpoint Inhibitors Nanobody Program Created through Immuno-oncology Collaboration AppendixPatent ScenarioIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.